Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 Patients

被引:2
作者
Million, Matthieu [1 ,2 ]
Lagier, Jean-Christophe [1 ,2 ]
Hourdain, Jerome [3 ,4 ]
Franceschi, Frederic [3 ,4 ]
Deharo, Jean-Claude [3 ,4 ]
Parola, Philippe [1 ,5 ]
Brouqui, Philippe [1 ,2 ]
机构
[1] IHU Mediterranee Infect, F-13005 Marseille, France
[2] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, Inst Rech Dev,Unite MEPHI Microbes Evolut Phylogen, F-13005 Marseille, France
[3] Ctr Hosp Univ Timone, AP HM, Serv Cardiol, F-13005 Marseille, France
[4] Aix Marseille Univ, Fac Sci Med & Paramed, C2VN, F-13005 Marseille, France
[5] Aix Marseille Univ, AP HM, Fac Sci Med & Paramed, VITROME,IRD, F-13005 Marseille, France
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 05期
关键词
COVID-19; SARS-CoV-2; hydroxychloroquine; azithromycin; QTc interval; cardiac rhythm; safety; torsades de pointe; COMBINATION; THERAPY;
D O I
10.3390/medicina59050863
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 +/- 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 +/- 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied.
引用
收藏
页数:12
相关论文
共 29 条
[1]  
American College of Cardiology, VENTR ARRH RISK HYDR
[2]  
[Anonymous], GLOB HCQ CQ STUD
[3]   Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit [J].
Bessiere, Francis ;
Roccia, Hugo ;
Deliniere, Antoine ;
Charriere, Rome ;
Chevalier, Philippe ;
Argaud, Laurent ;
Cour, Martin .
JAMA CARDIOLOGY, 2020, 5 (09) :1067-1069
[4]   COVID-19 Management at IHU Mediterranee Infection: A One-Year Experience [J].
Brouqui, Philippe ;
Drancourt, Michel ;
Raoult, Didier .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
[5]   Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 [J].
Cavalcanti, A. B. ;
Zampieri, F. G. ;
Rosa, R. G. ;
Azevedo, L. C. P. ;
Veiga, V. C. ;
Avezum, A. ;
Damiani, L. P. ;
Marcadenti, A. ;
Kawano-Dourado, L. ;
Lisboa, T. ;
Junqueira, D. L. M. ;
de Barros e Silva, P. G. M. ;
Tramujas, L. ;
Abreu-Silva, E. O. ;
Laranjeira, L. N. ;
Soares, A. T. ;
Echenique, L. S. ;
Pereira, A. J. ;
Freitas, F. G. R. ;
Gebara, O. C. E. ;
Dantas, V. C. S. ;
Furtado, R. H. M. ;
Milan, E. P. ;
Golin, N. A. ;
Cardoso, F. F. ;
Maia, I. S. ;
Hoffmann Filho, C. R. ;
Kormann, A. P. M. ;
Amazonas, R. B. ;
Bocchi de Oliveira, M. F. ;
Serpa-Neto, A. ;
Falavigna, M. ;
Lopes, R. D. ;
Machado, F. R. ;
Berwanger, O. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21) :2041-2052
[6]   Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature [J].
Chatre, Clotilde ;
Roubille, Francois ;
Vernhet, Helene ;
Jorgensen, Christian ;
Pers, Yves-Marie .
DRUG SAFETY, 2018, 41 (10) :919-931
[7]  
Chen D, 2020, medRxiv, DOI [10.1101/2020.02.27.20028530, 10.1101/2020.02.27.20028530, DOI 10.1101/2020.02.27.20028530, 10.1101/2020.02.27.20028530v1]
[8]   The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin [J].
Chorin, Ehud ;
Dai, Matthew ;
Shulman, Eric ;
Wadhwani, Lalit ;
Bar-Cohen, Roi ;
Barbhaiya, Chirag ;
Aizer, Anthony ;
Holmes, Douglas ;
Bernstein, Scott ;
Spinelli, Michael ;
Park, David S. ;
Chinitz, Larry A. ;
Jankelson, Lior .
NATURE MEDICINE, 2020, 26 (06) :808-809
[9]  
Coronavirus resource center, COVID 19 DASHB CTR S
[10]   Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases [J].
Costedoat-Chalumeau, N. ;
Hulot, J.-S. ;
Amoura, Z. ;
Leroux, G. ;
Lechat, P. ;
Funck-Brentano, C. ;
Piette, J.-C. .
RHEUMATOLOGY, 2007, 46 (05) :808-810